KYMERA THERAPEUTICS, INC. (KYMR)

Every figure this model derived for KYMR, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,194,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 690,985,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 737,265,000 AssetsCurrent 2026-06-30
current liabilities 71,326,000 LiabilitiesCurrent 2026-06-30
equity 1,509,256,000 StockholdersEquity 2026-06-30
interest expense 278,000 InterestPaidNet 2026-06-30
ocf -236,762,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 104,999,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 65,200,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up KYMR on one particular measure came for.

RatioValue
cash operating margin-263.57
current ratio10.34
current ratio reported10.34
deferred revenue growth-100.0
dilution pct12.6
fcf margin-226.63
growth cv3.47
interest cover-1259.63
operating margin-333.51
owner earnings margin-288.72
revenue growth134.84
revenue growth per share108.57
roic-33.71
rule of 40-198.67
sbc pct revenue62.1

What to be careful about

What this model itself distrusts about KYMR's figures. Written by the derivation as it ran, not added afterwards.